chr3-155144383-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_007289.4(MME):c.1342C>T(p.Arg448Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000713 in 1,612,384 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000072 ( 0 hom. )
Consequence
MME
NM_007289.4 stop_gained
NM_007289.4 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 4.13
Genes affected
MME (HGNC:7154): (membrane metalloendopeptidase) The protein encoded by this gene is a type II transmembrane glycoprotein and a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). The encoded protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL. This protein is not restricted to leukemic cells, however, and is found on a variety of normal tissues. The protein is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 3-155144383-C-T is Pathogenic according to our data. Variant chr3-155144383-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 504903.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-155144383-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MME | NM_007289.4 | c.1342C>T | p.Arg448Ter | stop_gained | 14/23 | ENST00000360490.7 | NP_009220.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MME | ENST00000360490.7 | c.1342C>T | p.Arg448Ter | stop_gained | 14/23 | 1 | NM_007289.4 | ENSP00000353679 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000658 AC: 10AN: 151954Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
10
AN:
151954
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000798 AC: 20AN: 250696Hom.: 0 AF XY: 0.0000812 AC XY: 11AN XY: 135490
GnomAD3 exomes
AF:
AC:
20
AN:
250696
Hom.:
AF XY:
AC XY:
11
AN XY:
135490
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000719 AC: 105AN: 1460430Hom.: 0 Cov.: 30 AF XY: 0.0000757 AC XY: 55AN XY: 726598
GnomAD4 exome
AF:
AC:
105
AN:
1460430
Hom.:
Cov.:
30
AF XY:
AC XY:
55
AN XY:
726598
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000658 AC: 10AN: 151954Hom.: 0 Cov.: 32 AF XY: 0.0000674 AC XY: 5AN XY: 74210
GnomAD4 genome
AF:
AC:
10
AN:
151954
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74210
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
4
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 19, 2022 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 32657593, 25525159, 34426522, 31589614, 34480178, 34307994, 31429185, 35304567, 15800120, 26991897, 25565308, 15464186, 27588448, 30609409, 30415211) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change creates a premature translational stop signal (p.Arg448*) in the MME gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MME are known to be pathogenic (PMID: 26991897). This variant is present in population databases (rs149905705, gnomAD 0.03%). This premature translational stop signal has been observed in individuals with Charcot-Marie-Tooth disease or neutral endopeptidase deficiency (PMID: 15464186, 27588448, 30415211). ClinVar contains an entry for this variant (Variation ID: 504903). For these reasons, this variant has been classified as Pathogenic. - |
MME-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 21, 2024 | The MME c.1342C>T variant is predicted to result in premature protein termination (p.Arg448*). This variant was first reported in the compound heterozygous state in an individual with neutral endopeptidase deficiency who, in a retrospective study, developed Charcot-Marie-Tooth disease type 2 (CMT2, Debiec et al. 2004. PubMed ID: 15464186; Nortier et al. 2021. PubMed ID: 34307994). This variant has also been reported in the compound heterozygous or homozygous state in several unrelated individuals with CMT2 (Lupo et al. 2018. PubMed ID: 30415211), as well as autosomal recessive distal hereditary motor neuropathy (Hong et al. 2019. PubMed ID: 31429185). In addition, this variant has been reported in the heterozygous state in an individual with late-onset axonal neuropathies (individual US6/II-1 in Auer-Grumbach et al. 2016. PubMed ID: 27588448). In vitro functional studies using HEK293 cells demonstrated that expression of this variant results in significantly decreased mRNA levels and enzymatic activity (Hong et al. 2019. PubMed ID: 31429185). This variant is reported in 0.031% of alleles in individuals of Latino descent in gnomAD, and has been consistently interpreted as pathogenic by other laboratories in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/504903/). Nonsense variants in MME are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 28, 2016 | The p.Arg448X variant in MME has been reported in one compound heterozygote moth er with NEP deficiency who had a child with neonatal membranous glomerulopathy ( Debiec 2004). This variant has also been identified in 4/120,898 of chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs149905705). Although this variant has been seen in the general population, it s frequency is low enough to be consistent with a recessive carrier frequency. T his nonsense variant leads to a premature termination codon at position 448, whi ch is predicted to lead to a truncated or absent protein. Loss of function of th e MME gene in a mother is associated with fetomaternal alloimmunisation leading to fetal membranous glomerulopathy when a fetus has the normal MME gene copy. In summary, this variant meets our criteria to be classified as pathogenic for NEP deficiency (responsible for alloimmune antenatal membranous nephropathy) bas ed upon its co-occurrence with another disease-causing variant in an affected in dividual and the predicted functional impact. - |
Spinocerebellar ataxia 43 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Nov 14, 2019 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1,PM1,PM2. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A;A;A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at